Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires Shares of 318,743 Teva Pharmaceutical Industries Ltd. $TEVA

Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 318,743 shares of the company’s stock, valued at approximately $9,948,000.

A number of other hedge funds have also recently bought and sold shares of the business. Global Retirement Partners LLC grew its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Banque Cantonale Vaudoise grew its stake in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares in the last quarter. Ethic Inc. grew its stake in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares in the last quarter. Allworth Financial LP grew its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling

In other news, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. UBS Group raised their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.78.

Get Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $34.21 on Monday. The firm has a market cap of $39.34 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 3.49 and a beta of 0.84. The stock has a 50 day moving average of $32.82 and a 200-day moving average of $31.68. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

About Teva Pharmaceutical Industries

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Featured Articles

• Five stocks we like better than Teva Pharmaceutical Industries
• These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
• 3 Stocks Under $20 to Buy Before a Broader Market Rally
• Petco Faces Tough Competition, But Momentum Is Building
• The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).